Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
DARE Dare Bioscience Inc
- Stocks
- Healthcare
- NASDAQ: DARE
Price (delayed)
$2.64
Market cap
$23.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.17
Enterprise value
$16.61M
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. The company's mission is to identify, develop and bring to market a diverse
Highlights
The company's gross margin has surged by 126% QoQ and by 125% YoY
DARE's EPS has surged by 96% year-on-year and by 65% since the previous quarter
DARE's revenue has soared by 165% QoQ but it has shrunk by 99% YoY
The equity has plunged by 59% from the previous quarter but it has grown by 13% YoY
The debt has soared by 174% since the previous quarter and by 118% year-on-year
The company's gross profit has shrunk by 98% YoY
Key stats
What are the main financial stats of DARE
Market
Valuations
Earnings
Shares outstanding
8.85M
Market cap
$23.37M
Enterprise value
$16.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
892.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
641
Revenue
$25,909
Gross profit
$58,583
Operating income
-$22.01M
Net income
-$1.68M
EBIT
-$1.68M
EBITDA
-$1.49M
Free cash flow
$6.01M
Per share
Balance sheet
Liquidity
EPS
-$0.17
EPS diluted
-$0.18
Free cash flow per share
$0.69
Book value per share
-$1.08
Revenue per share
$0
TBVPS
$2.13
Total assets
$18.62M
Total liabilities
$28.18M
Debt
$3.57M
Equity
-$9.56M
Working capital
-$9.37M
Debt to equity
-0.37
Current ratio
0.56
Quick ratio
0.49
Net debt/EBITDA
4.54
Margins
Efficiency
Dividend
EBITDA margin
-5,738.9%
Gross margin
226.1%
Net margin
-6,470.9%
Operating margin
-84,951.7%
Return on assets
-8.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-6,470.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DARE stock price
How has the Dare Bioscience stock price performed over time
Intraday
-1.12%
1 week
-9.59%
1 month
-8.97%
1 year
-49.13%
YTD
-15.38%
QTD
-8.65%
Financial performance
How have Dare Bioscience's revenue and profit performed over time
Revenue
$25,909
Gross profit
$58,583
Operating income
-$22.01M
Net income
-$1.68M
Gross margin
226.1%
Net margin
-6,470.9%
DARE's revenue has soared by 165% QoQ but it has shrunk by 99% YoY
The company's gross margin has surged by 126% QoQ and by 125% YoY
The company's gross profit has shrunk by 98% YoY
DARE's net income has surged by 94% year-on-year and by 59% since the previous quarter
Price vs fundamentals
How does DARE's price correlate with its fundamentals
Growth
What is Dare Bioscience's growth rate over time
Valuation
What is Dare Bioscience stock price valuation
P/E
N/A
P/B
N/A
P/S
892.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
641
DARE's EPS has surged by 96% year-on-year and by 65% since the previous quarter
The equity has plunged by 59% from the previous quarter but it has grown by 13% YoY
DARE's revenue has soared by 165% QoQ but it has shrunk by 99% YoY
The price to sales (P/S) is 3.9% lower than the last 4 quarters average of 928.4
Efficiency
How efficient is Dare Bioscience business performance
The ROA has soared by 94% YoY and by 62% from the previous quarter
DARE's return on sales has surged by 84% since the previous quarter
Dividends
What is DARE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DARE.
Financial health
How did Dare Bioscience financials performed over time
The total assets is 34% less than the total liabilities
The company's quick ratio rose by 48% YoY but it fell by 34% QoQ
The total assets has grown by 43% YoY but it has contracted by 16% from the previous quarter
The debt is 137% greater than the equity
The debt has soared by 174% since the previous quarter and by 118% year-on-year
The debt to equity has plunged by 147% YoY and by 68% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.